Rotavirus

Beyond Ebola, keeping patients and health workers safe

Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
 
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.
 
Undefined

Vaccine in National Immunization Programme Update

WHO, UNICEF, and partners, are in regular dialogue with countries to support effective preparations.

Click here to access the downloadable PowerPoint file from the WHO website or simply click on the image below to read updates on vaccine in national immunization programmes.

Undefined

Nepal earthquakes: How medics race to avert a health crisis

Three weeks, two earthquakes. More than 8,000 deaths and 17,000 injuries. Nearly 3 million displaced and more than 4 million people affected.

Nepal was brought tumbling down through a series of disasters beyond its control. The collapse of buildings may have ceased -- for now -- but the lives of Nepal's residents remain at risk with the deluge of health consequences now facing them.

Undefined

Gut Microbes May Help Determine Our Immune Response to Vaccines

Rotavirus used to infect most youngsters until a widely available oral vaccine came out in 2006. The virus, which causes severe diarrhea and thus life-threatening dehydration, still kills more than 450,000 kids globally every year, largely in Asia and Africa, because the vaccine is not always effective. Vanessa Harris of the University of Amsterdam wanted to find out why infants in those regions have such high rates of so-called nonresponders. Perhaps, she reasoned, the microbes that live in a child's large intestine played a role.

Undefined

Mexico suspends infant vaccines after two babies die and 29 fall ill

Mexico’s public health system has suspended infant vaccines and begun an investigation after two babies died and 29 became ill in an impoverished community in southern Mexico.
 
The Mexican institute for social security says six of the 29 babies are in grave condition after receiving vaccinations for tuberculosis, rotavirus and hepatitis B.
 
The cause of the adverse reactions is not known, the institute said Sunday.
 
Undefined

Immunization coverage

Key facts
 
  • Immunization prevents illness, disability and death from vaccine-preventable diseases including cervical cancer, diphtheria, hepatitis B, measles, mumps, pertussis, pneumonia, polio, rotavirus diarrhoea, rubella and tetanus.
  • Global vaccination coverage is holding steady.
  • Immunization currently averts an estimated 2 to 3 million deaths every year.
  • But an estimated 21.8 million infants worldwide are still missing out on basic vaccines.
 
Overview
 
Undefined

Bharat Biotech makes a splash on rotavirus with help from Indian PM Modi

Want to get maximum publicity for your drug launch? Have your nation's leader announce it. Most newspapers in India carried the story of the launch of a locally made vaccine, as announced by Prime Minister Narendra Modi.
 
To be sure, Bharat Biotech's oral Rotavac for preventing rotavirus is India's first locally made vaccine for the virus and is to be the world's cheapest at less than a $1 a dose in a three-dose regimen. And there are only two other rotavirus vaccines on the global market.
 
Undefined

Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck

Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline ($GSK) and Merck ($MRK). Now, it's ready to make good on its promise.
 
The country has rolled out Bharat's three-dose vaccine, Rotavac, at a rate of around 60 rupees--or just under one U.S. dollar.
 
Undefined

Gates Foundation bets $52M on CureVac's mRNA promise

The Bill and Melinda Gates Foundation is throwing its weight behind CureVac, a German biotech working to transform patients' cells into drug factories, committing $52 million in hopes of crafting vaccines for the developing world.
 
Undefined

Pages